there seems to be some heavy resistance around these level with a lot of potential upside.

Triumeq US Approval

London, UK, 22 August, 2014 - ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq® (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection.1 Triumeq is ViiV Healthcare's first dolutegravir-based fixed-dose combination, offering many people living with HIV the option of a single-pill regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir, with the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine.

more..

From 1365 intraday low on 8 August to 1462 today... the comeback kid.

Well done Midknight - I bought @1,386, sold half +55 and bought them back 11p lower.

So far, so good.

Ebola

Good find Midkinght - shaping up rather well!

Triumeq receives EU approval

GlaxoSmithKline plc (LSE:GSK) today announced that ViiV Healthcare Ltd (a global specialist HIV company with GlaxoSmithKline, Pfizer, Inc. and Shionogi Limited as shareholders) is issuing the following statement today:

ViiV Healthcare receives EU marketing authorisation for Triumeq® (dolutegravir/abacavir/lamivudine), a new once-daily single-pill regimen for the treatment of HIV

Once this area of noise is behind, hopefully a move to @1540 PDQ.

Ebola vaccine latest

GSK Advair alternative launched

Sept 8: Credit Suisse: Underperform - TP: 1400p

Publication positive study results mepolizumab

New England Journal of Medicine and ERS publish positive results from GSK phase III studies of mepolizumab in patients with severe eosinophilic asthma.

Deutsche Bank Hold 1,430.25 1,500.00 1,500.00 Retains

GSK China consumer healthcare unit linked to DOJ probe in 2012

(Reuters) - A U.S. anti-bribery probe into GlaxoSmithKline Plc touched on the firm's Chinese consumer healthcare business in 2012, internal documents show, suggesting the drugmaker's compliance problems in China could go wider than previously revealed.

GSK confirmed it had conducted an investigation into procurement practices in consumer healthcare in China, but said it did not find any "unethical conduct". It said the inquiry was unrelated to a Chinese criminal investigation into corruption in its pharmaceuticals division that was made public last year.

Sept 10: Deutsche; Hold - TP: 1500p - Reiterates.

Seems to be Deutsche's new baby.

Well I hope they have more success here than with TW.!!

They seem to have gone cold on TW....

Sept 11;
Berenberg; Hold - TP: 1575p
JP Morgan: Neutral - No TP

Their last TP was £17 on 17 June, so I guess that still stands.

Yesterday's JPMorgan TP was 1446p.

Midknight - their last TP on 17 Jun was £17 - GSK Broker notes

Skinny, if interested you can get a daily email update re brokers' forecasts for all stocks
here. I never give my name or anything personal. Just email address.